Heron Therapeutics | HRTX - Vertriebs- Und Verwaltungskosten





Vertriebs- Und Verwaltungskosten Veränderung Datum
ALKERMES USD 190.54M 6.1M 2026-09
Alnylam Pharmaceuticals USD 342M 5.92M 2026-09
Amarin USD 18.97M 1.03M 2025-12
ANI Pharmaceuticals USD 94.86M 3.2M 2026-09
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.63M 4.88M 2026-06
Eisai JPY 114.83B 4.71B 2026-06
Emergent BioSolutions USD 182.8M 82.3M 2023-06
GlaxoSmithKline GBP 2.16B 39M 2026-09
Heron Therapeutics USD 23.74M 605K 2025-12
Insmed USD 253.03M 5.56M 2026-09
Ligand Pharmaceuticals USD 72.62M 43.49M 2026-09
Merck USD 2.86B 25M 2026-09
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Neurocrine Biosciences USD 366.3M 16.8M 2026-09
Omeros USD 11.32M 2.48M 2024-09
Pacira USD 950.8M 858.99M 2026-09
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Ultragenyx Pharmaceutical USD 97M 9M 2026-09
Veracyte USD 57.95M 2.25M 2026-09
Vertex Pharmaceuticals USD 556.3M 25.9M 2026-09